E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Increased muscle tone in lower extremity or extremities leading to difficulties of movement and walking. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10041416 |
E.1.2 | Term | Spasticity |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to assess the efficacy of MYOBLOC versus placebo in the treatment of adult lower limb spasticity. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this trial are: • To establish a dose response between 2 active doses of MYOBLOC versus placebo. • To assess the duration of therapeutic response after a single administration of MYOBLOC. • To evaluate the long-term safety and tolerability of MYOBLOC after multiple administrations at approximately 13-week intervals over a minimum duration of 1 year. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Able to understand the potential risks and benefits, the study requirements, and provide written informed consent before enrollment into the study; if unable, the subject’s Legally Authorized Representative (LAR) may provide written informed consent. 2. Male or female ≥18 to maximum of 80 years of age, inclusive. 3. Lower limb spasticity due to stroke or TBI that occurred ≥6 months prior to randomization. Eligible subjects may have lower limb monoplegia or hemiplegia. 4. Ambulatory (with or without the use of a walking assistive device). 5. Modified Ashworth Scale (MAS) score ≥2 in the ankle plantar flexors of the affected lower limb at screening and at baseline. 6. In the Investigator’s opinion, the subject will be available and able to comply with the study requirements for at least 1 year, based on the subject’s overall health and disease prognosis. 7. In the Investigator’s opinion, the subject will be willing and able to comply with all requirements of the protocol, including completion of study questionnaires. A caregiver may be designated to assist with the physical completion of questionnaires/scales. |
|
E.4 | Principal exclusion criteria |
1. Quadriplegia/tetraplegia, lower limb diplegia or triplegia. 2. Uncontrolled epilepsy with a seizure(s) within the previous year. 3. Neuromuscular disorders including, but not limited to, amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), multiple sclerosis (MS), myasthenia gravis, or muscular dystrophy. 4. History of major joint contracture(s), in which, based on Investigator assessment, the contracture(s) significantly contribute to joint immobility in the target limb. 5. Unresolved fracture(s) in the lower limb identified for treatment. 6. Severe atrophy in the lower limb identified for treatment. 7. Known hypersensitivity to botulinum toxins type A or B or to any MYOBLOC solution components. 8. Concomitant use or exposure within 5 half-lives of randomization of the following: aminoglycoside antibiotics, curare-like agents, or other agents that may interfere with neuromuscular function. 9. Treatment with a neurolytic agent (e.g., phenol, alcohol blocks) to the lower limb identified for treatment within 1 year before randomization. 10. Presence of a spinal stimulator or intrathecal baclofen pump that has not been turned off within 30 days before screening. 11. Changes to treatment regimen or any new treatment with oral antispasmodics and/or muscle relaxants within 30 days before randomization. 12. Initiation of physical and/or occupational therapy <30 days before randomization. Subjects receiving physical and/or occupational therapy >30 days before randomization must be willing to maintain their therapy regimen through Week 4 of the DBP of the study. 13. Application of an ankle-foot orthosis (AFO) <30 days before randomization. Subjects regularly using an AFO >30 days before randomization must be willing to maintain use of the AFO through Week 4 of the DBP of the study. 14. Prior botulinum toxin typeA (BoNT/A) or B (BoNT/B) treatment in the lower limb identified for treatment within 24 weeks before screening. Prior BoNT/A or BoNT/B treatment in areas other than the lower limb identified for treatment is not exclusionary but must have occurred at least 12 weeks before screening. Prior toxin exposure must have been well tolerated and without any significant long-term side effects in the case of repeated prior exposure. 15. Subjects should not receive nor have any plans for receiving any botulinum toxin treatment, other than the study drug (MYOBLOC), from the point informed consent is obtained until participation is complete. 16. Severe dysphagia (i.e., inability to swallow liquids, solids or both without choking or medical intervention), or dysphagia with a history of aspiration pneumonia, within 6 months before screening. 17. Prior surgery to treat spasticity in the lower limb selected for treatment (i.e., tendon lengthening or tendon transfer). 18. Any anticipated or scheduled surgery during the study period, with the exception of dermatological procedures performed under local anesthesia for the purposes of removing precancerous and cancerous lesions. 19. Major surgery within 30 days before screening. 20. Pregnancy or breastfeeding. 21. Females of childbearing potential must agree to practice a medically acceptable method of contraception (e.g., intrauterine device, hormonal contraception started at least one full cycle before study enrollment or barrier method in conjunction with spermicide) for the duration of the study (including 2 months after study completion). For the purposes of this study, all females are considered to be of childbearing potential unless they are confirmed by the Investigator to be post-menopausal (at least 1 year since last menses), biologically sterile, or surgically sterile (e.g., hysterectomy, bilateral oophorectomy, tubal ligation). 22. History of drug or alcohol abuse within 6 months before screening. 23. Obstructive pulmonary disease with forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <70%. 24. Slow vital capacity (SVC) <60% of predicted. 25. Chronic or current use of inhaled corticosteroids. 26. Ventilator dependence. 27. Infection at the planned sites of injection. 28. Treatment with an investigational drug, device, or biological agent within 30 days before randomization or while participating in this study. 29. Malignancy diagnosed 3 months before screening. 30. Any other medical illness, condition, or clinical finding that, in the opinion of the Investigator and/or the Sponsor, would put the subject at undue risk. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase 2 and Phase 3 of the Double-Blind Period: • Change from baseline in tone of the ankle plantar flexors as measured by the MAS at Week 4 post-injection • Clinical Global Impression of Change (CGI-C) in functional ability at Week 4 postinjection |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary Efficacy endpoints: Phase 2 and Phase 3 of the Double-Blind Period Change from baseline at Week 4 post-injection in: • Patient Global Impression of Change (PGI-C) • Caregiver Global Impression of Change (GGI-C) • Pain-NRS • WIQ • WRCS • Responder analysis, defined as a subject with at least a 1-point decrease in the MAS score at Week 4 in the ankle plantar flexors Change from baseline at Weeks 2, 8, and 13 and if applicable, at reevaluation visits in: • Tone in the ankle plantar flexors as measured by the MAS • CGI-C and CGI-S • PGI-C and PGI-S • GGI-C and GGI-S • Pain-NRS • WIQ • WRCS • Responder analysis, defined as a subject with at least a 1-point decrease in the MAS score at Weeks 2, 8, and 13 in the ankle plantar flexors
Safety Endpoints: Phase 2 and Phase 3 of the Double-Blind Period and Open-Label Extension • Occurrence, seriousness, severity, and causality assessment of AEs • Vital signs (systolic/diastolic blood pressure, pulse, respiration rate, and temperature) • Serum chemistry, hematology, and urinalysis • Neurologic exam findings • Pulmonary function findings (spirometry) • C-SSRS |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
randomized, double-blind, placebo-controlled followed by open-label extension |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Czech Republic |
Hungary |
Poland |
Russian Federation |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 7 |